NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US) Roundtable on Translating Genomic-Based Research for Health. The Value of Genetic and Genomic Technologies: Workshop Summary. Washington (DC): National Academies Press (US); 2010.

Cover of The Value of Genetic and Genomic Technologies

The Value of Genetic and Genomic Technologies: Workshop Summary.

Show details

References

  1. Anderson JL, Horne BD, Stevens SM, Grov AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116(22):2563–2570. [PubMed: 17989110]
  2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest. 8th Edition. 6 Suppl. Vol. 133. 2008. pp. 160S–198S. [PubMed: 18574265]
  3. Caraco YS, Blotnic S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin Pharmacol Ther. 2008;83(3):460–470. [PubMed: 17851566]
  4. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73–83. [PubMed: 19153410]
  5. EGAPP (Evaluation of Genomic Applications in Practice and Prevention) Working Group. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35–41. [PMC free article: PMC2743612] [PubMed: 19125126]
  6. Flockhart DA, O’Kane D, Williams MS, Watson MS. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10(2):139–150. [PubMed: 18281922]
  7. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–5788. [PMC free article: PMC2645108] [PubMed: 18809606]
  8. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690–1698. [PubMed: 11926893]
  9. Hughes DA, Pirmohamed M. Warfarin pharmacogenetics: Economic considerations. Pharmacoeconomics. 2007;25(11):899–902. [PubMed: 17960949]
  10. IWPC (International Warfarin Pharmacogenetics Consortium) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–764. [PMC free article: PMC2722908] [PubMed: 19228618]
  11. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009;24(5):656–664. [PMC free article: PMC2669873] [PubMed: 19306050]
  12. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008;83(2):312–321. [PMC free article: PMC2683398] [PubMed: 17653141]
  13. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010;28(1):61–74. [PubMed: 20014877]
  14. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12(2):93–104. [PubMed: 20084010]
  15. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2009;2(5):429–436. [PubMed: 20031873]
  16. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285–2293. [PubMed: 15930419]
  17. USPSTF (U.S. Preventive Services Task Force) Guide to Clinical Preventive Services. 2nd Edition. 1996. [accessed May 18, 2010]. Available at www​.ncbi.nlm.nih.gov/bookshelf/br​.fcgi?book=hscps2ed1996.
  18. Veenstra DL. The cost-effectiveness of warfarin pharmacogenomics. J Thromb Haemost. 2007;5(9):1974–1975. [PubMed: 17650084]
Copyright © 2010, National Academy of Sciences.
Bookshelf ID: NBK52759

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...